Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases
K Ulu, M Çakan, Ş Çağlayan, RE Yiğit… - Expert Opinion on …, 2023 - Taylor & Francis
Background We aimed to compare the efficacy and safety of the original product (OP) and
biosimilar product (BP) of adalimumab in pediatric rheumatic diseases. Research design …
biosimilar product (BP) of adalimumab in pediatric rheumatic diseases. Research design …
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities
A Öksel, HE Sönmez, N Şahin - Expert Opinion on Biological …, 2025 - Taylor & Francis
Introduction Biosimilars are biologic medications designed to closely replicate the properties
of previously approved biologic disease-modifying anti-rheumatic drugs (bDMARDs). They …
of previously approved biologic disease-modifying anti-rheumatic drugs (bDMARDs). They …
Clinical efficacy of biosimilar switch of adalimumab for management of uveitis
GM Murray, N Griffith, P Sinnappurajar… - Ocular Immunology …, 2024 - Taylor & Francis
Background Adalimumab has demonstrated efficacy in non-infectious uveitis. With the
introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and …
introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and …
Impact of HLA-B51 on uveitis and retinal vasculitis: data from the AIDA International Network Registries on ocular inflammatory disorders
Purpose The clinical relevance of human leukocyte antigen (HLA) subtypes such as HLA-
B51 on Behçet's disease (BD)-related uveitis and non-infectious uveitis (NIU) unrelated to …
B51 on Behçet's disease (BD)-related uveitis and non-infectious uveitis (NIU) unrelated to …
Biosimilars Versus Originators in Children With Juvenile Idiopathic Arthritis: A Real-World Experience
MF Gicchino, G Capasso, A Amodio… - Journal of Pediatric …, 2025 - Elsevier
Introduction We aimed to evaluate the efficacy, safety, and immunogenicity profile of
Etanercept (ETA) and Adalimumab (ADA) biosimilars (BIOs) compared to their originators in …
Etanercept (ETA) and Adalimumab (ADA) biosimilars (BIOs) compared to their originators in …
Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry
M Tarsia, A Vitale, C Gaggiano, J Sota… - Ophthalmology and …, 2024 - Springer
Introduction Since many biological drug patents have expired, biosimilar agents (BIOs) have
been developed; however, there are still some reservations in their use, especially in …
been developed; however, there are still some reservations in their use, especially in …
Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study
X Xu, X Liu, W Zheng, J **ao, X Li, L Wu, L Zou… - Frontiers in …, 2022 - frontiersin.org
Background Etanercept biosimilar recombinant human TNF-α receptor II: IgG Fc fusion
protein (rhTNFR-Fc) has showed its efficacy and safety in Chinese patients with rheumatoid …
protein (rhTNFR-Fc) has showed its efficacy and safety in Chinese patients with rheumatoid …
Embracing change: an international survey study on the beliefs and attitudes of pediatric rheumatologists towards biosimilars
Background Biosimilars have been adopted by clinicians more slowly than anticipated in the
post-marketing phase. Objectives We aimed to reveal the perceptions and attitudes of …
post-marketing phase. Objectives We aimed to reveal the perceptions and attitudes of …
Biosimilars in Pediatric Rheumatology
D ÜNAL, E ALİYEV, Y BİLGİNER - Turkiye Klinikleri Pediatric …, 2024 - turkiyeklinikleri.com
Targeted biological therapies have become a significant component of treating rheumatic
diseases since the introduction of the first tumor necrosis factor (TNF) inhibitor in 1998. The …
diseases since the introduction of the first tumor necrosis factor (TNF) inhibitor in 1998. The …